News & Updates
Filter by Specialty:
Mid-dose beta-blocker therapy tied to highest mortality reduction after AMI
Use of any beta-blocker dose results in a significant decrease in mortality following acute myocardial infarction (AMI) when compared with no treatment, reports a study. Doses >25 percent to 50 percent of the currently recommended target dose (RTD) are associated with highest mortality reduction within the first year after AMI, indicating that higher doses are not required.
Mid-dose beta-blocker therapy tied to highest mortality reduction after AMI
09 May 2023
Bisphosphonate, denosumab not linked to acute cardiovascular risk
Use of oral bisphosphonate or denosumab does not appear to increase the risk of cardiovascular events (CVEs), namely acute myocardial infarction, unstable angina, cerebrovascular accident, and transient ischemic attack, in persons with incident fracture, a study has shown.
Bisphosphonate, denosumab not linked to acute cardiovascular risk
06 May 2023
Perampanel for idiopathic generalized epilepsy passes muster in real world
Perampanel appears to be effective and have good tolerability in patients with idiopathic generalized epilepsy treated in everyday clinical practice settings, as shown in a study.
